Navigation Links
Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
Date:2/17/2009

SAN DIEGO, Feb. 17 /PRNewswire/ -- Tracon Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that its three clinical stage cancer therapeutics (TRC105, TRC102, and TRC093) will be presented at the 100th Annual Meeting of the American Association for Cancer Research this April 18-22 in Denver, Colorado. "Each program targets a unique pathway with the potential for broad application to a wide variety of cancer types, and we are pleased that all three will be presented at this year's meeting" explained Bryan Leigh, MD, Chief Medical Officer at Tracon Pharmaceuticals.

TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105, a membrane receptor required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. Clinical data from a phase 1 first-in-human study of TRC105 therapy for advanced cancer was recently presented at the 11th International Symposium on Anti-Angiogenic Agents in San Diego, CA by Michael S. Gordon, MD (Premiere Oncology, Scottsdale, AZ). TRC105 may also be a useful therapy for age-related macular degeneration, the most common cause of blindness in people over the age of 50.

TRC102 is a small molecule inhibitor of base excision repair that improves the therapeutic index of commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an i.v. agent in combination with temozolomide (Temodar(R)).

TRC093 is a humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor growth, and metastasis by binding cleaved collagen in the extracellular matrix of cancers. This antibody is expected to address multiple solid tumor types and may also be developed for age-relate
'/>"/>

SOURCE Tracon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009
2. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
3. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
4. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
5. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
6. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
7. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
8. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
9. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
11. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... health record becomes widespread across the United States, due ... Act, the quantity of clinical data that will become ... increase. Additionally, experts in healthcare have become increasingly ... data for the purpose of gleaning insights that have ... a process that is known as big data. ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... down may help ease the hot flashes that often accompany ... for more than 50 percent of menopausal women, said Dr. ... reproductive science at the Icahn School of Medicine at Mount ... women experience more than 10 hot flashes a day, and ...
(Date:7/10/2014)... felt better prepared to respond to an active shooter ... new study in the journal Prehospital and Disaster ... examine the EMS provider comfort level with respect to ... been neutralized or working with law enforcement personnel during ... School shooting, the Virginia Tech campus shooting, the 2009 ...
(Date:7/10/2014)... the "Mississippi baby" an infant seemingly cured of HIV ... remission of HIV infection in The New England Journal ... after more than two years of not taking antiretroviral therapy ... and researchers involved in the case. , "Certainly, ... child, the medical staff involved in the child,s care, and ...
(Date:7/10/2014)... Estonian-born Katerina Alba,s research at the University of Huddersfield ... the most popular emulsion-based food products such as ... is starting to gain an international profile for her ... and food science at the University and now she ... with her supervisor, Dr Vassilis Kontogiorgos, she is investigating ...
Breaking Medicine News(10 mins):Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:World interest in research work on the benefits of the Okra plant 2
... -- Health care coverage increased dramatically in parts of ... interventions were implemented to improve access to health care, ... new research by Brown University sociologist Susan E. Short ... findings appear in the December issue of Health ...
... More than half a million children in the U.S. ... suffer TBI often report headaches afterward, but little is known ... a significant new study, "Headache After Pediatric Traumatic Brain ... three and 12 months after mild, moderate or severe TBI ...
... of paid sick leave, contributed to higher risk of exposure ... U.S. during the 2009 H1N1 pandemic, according to a study ... senior associate director of the Maryland Center for Health Equity ... findings are published online ahead of print in the ...
... HealthDay Reporter , MONDAY, Dec. 5 (HealthDay News) -- ... nearly three times higher risk of having an autism ... used national birth data that included nearly 656,000 children ... 428,000 women. Using a national prescription drug registry, they ...
... 5 (HealthDay News) -- There,s been a large increase in the ... 2002, a trend that may help ease concerns about a predicted ... data and found that the number of RNs aged 23 to ... fewer than 110,000 by 1991 and remained low for the next ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... women in New Hampshire, which has high levels of arsenic ... arsenic through rice. The study, published in this ... did not look for any potential health problems. However, other ...
Cached Medicine News:Health News:Chinese health coverage increases with new government efforts 2Health News:Chinese health coverage increases with new government efforts 3Health News:Study finds headaches after traumatic brain injury highest in adolescents and girls 2Health News:Study finds headaches after traumatic brain injury highest in adolescents and girls 3Health News:Maryland study finds that US Hispanics were at greater risk for H1N1 flu during 2009 pandemic 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 3Health News:Good News for Those Worried About U.S. Nursing Shortage 2Health News:Study Sees Rice as Source of Arsenic Exposure 2Health News:Study Sees Rice as Source of Arsenic Exposure 3
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:1/15/2014)... MILTON, N.Y. , Jan. 15, 2014 Sono-Tek Corporation ... three months ended November 30, 2013, compared to sales of ... or 20%. Once again, this quarter has also shown growth ... in the first quarter of this fiscal year. Markets that ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... its Medical Software Advice website ( www.softwareadvice.com/medical ), a ... the right technology for their practices. , , ,"The ... vendor landscape is more fragmented than ever," said Don ... "We aim to bring clarity to the market ...
... 17 Schering-Plough,Corporation (NYSE: SGP ) today ... a fast-dissolving, sublingual tablet being,developed for treatment of ... in treating patients with acute schizophrenia., According ... and 10 mg twice,daily were both significantly more ...
Cached Medicine Technology:Physicians Will Benefit from Medical Software Advice Website 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... The Series I Instrument program offers ... low profile, while maintaining strength and durability. ... pathology in tight joint spaces. Series I ... cutting tip style, size and angle required ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
Medicine Products: